Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.63 |
| ▸ | TNKS | O95271 | 3/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040941 | 0.84 | CRBN (0.66) | CRBNDDB1TNKSTNKS2 | |
| SCHEMBL31040949 | 0.82 | CRBN (0.63) | CRBNDDB1TNKSTNKS2ALOX5 | |
| SCHEMBL31607792 | 0.82 | CRBN (0.63) | CRBNDDB1TNKS | |
| SCHEMBL25575697 | 0.78 | CRBN (1.00) | CRBNDDB1TNKSTNKS2ALOX5 | |
| SCHEMBL31040970 | 0.78 | CRBN (1.00) | CRBNDDB1TNKSTNKS2ALOX5 | |
| SCHEMBL31607788 | 0.76 | CRBN (0.72) | CRBNDDB1TNKSTNKS2ALOX5 | |
| SCHEMBL31543831 | 0.76 | CRBN (0.55) | CRBNDDB1TNKSTNKS2KDM4E | |
| SCHEMBL31040943 | 0.73 | CRBN (0.69) | CRBNDDB1TNKSTNKS2ALOX5 | |
| SCHEMBL23121404 | 0.73 | CRBN (0.63) | CRBNDDB1TNKSKDM4EALDH1A1 | |
| SCHEMBL31040963 | 0.73 | CRBN (0.63) | CRBNDDB1TNKSALOX5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRBN, CUL1, CUL5 | CRBN 1/4885DDB1 188/4885TNKS 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.